An announcement from Day One Biopharmaceuticals ( (DAWN) ) is now available.
Samuel Blackman, co-founder of Day One Biopharmaceuticals, plans to retire as Head of Research & Development by the end of 2024, transitioning to a strategic advisor role. His departure marks a significant leadership change as the company searches for his successor, acknowledging his pivotal contributions since its inception.
See more insights into DAWN stock on TipRanks’ Stock Analysis page.